[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiuhua Sun\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100574640","phase-4-bv-in-the-treatment-of-relapsedrefractory-hodgkin-lymphoma-100574640",false,"NCT06761911","BV in the Treatment of Relapsed\u002Frefractory Hodgkin Lymphoma","A Real-world Study of Brentuximab Vedotin Monotherapy and Combination Regimens in the Treatment of Relapsed\u002FRefractory Hodgkin Lymphoma","Inclusion Criteria:\n\n* Histologically, classical hodgkin lymphoma（cHL） was diagnosed and relapsed or refractory.\n* Patients were treated with BV-containing regimen at least once\n* Presence of tumor (measurable or nonmeasurable).\n* Signature of the form consent for participation in the study.\n\nExclusion Criteria:\n\n* \\\u003C18 years","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to explore the real-world Chinese relapsed\u002Frefractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are:\n\nTo evaluate the efficacy and toxicity of BV-containing regimen in relapsed\u002Frefractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.",[26],"Hodgkin Lymphoma (Category)",[28,29,30,31,32],"Brentuximab Vedotin","Hodgkin lymphoma","refractory recurrence","real world","china","NOT_YET_RECRUITING","2025-01-06",{"date":36,"type":37},"2025-01-07","ACTUAL",{"date":39,"type":20},"2024-12-31",{"date":41,"type":20},"2026-01-31",{"name":43,"class":44},"Xiuhua Sun","OTHER",""]